Szczepionki nowej generacji przeciw zakazeniu wirusem influenzy koni

• Autorzy: Purzycka M , Rozek W. , Zmudzinski J.F.

Warianty tytułu

EN

New generation of vaccines against equine influenza virus infection

• Języki publikacji: PL

Abstrakty

EN

Influenza virus is the main etiological agent of respiratory diseases in horses. Equine influenza virus is represented by two different serotypes: H7N7 and H3N8. The H7N7 strain has not been isolated since 1980 and H3N8 circulates in equine population throughout most of the world. Inactivated and subunit vaccines are most commonly used in order to prevent infections. These vaccines, in contrast to natural infections, do not induce either cytotoxic lymphocytes T or mucosal antibodies, nor do they provide long-lasting immunity. The introduction of new types of vaccines has become necessary and the first group of new generation vaccines is those containing live viral strains. They may be produced by attenuation in low temperature or by reverse genetics. Viral vector vaccines may be included in this group of vaccines. The next group of new generation of vaccines consists of a DNA vaccine and an inactivated vaccine with new adjuvants.

Słowa kluczowe

PL

influenza koni; skutecznosc; szczepienia ochronne; profilaktyka; szczepionki nowej generacji; choroby zwierzat; konie

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2007
• Tom: 63
• Numer: 11
• Opis fizyczny: s.1281-1284,bibliogr.

Twórcy

autor

Purzycka M

• Panstwowy Instytut Weterynaryjny - Panstwowy Instytut Badawczy, Al.Partyzantow 57, 24-100 Pulawy

autor

Rozek W.

autor

Zmudzinski J.F.

Bibliografia

• 1.Anon.: Conclusions and recommendations from the Expert Surveillance Panel on Equine Influenza Vaccines. OIE Bulletin 2006, 2, 35-36.
• 2.Breathnach C. C., Clark H. J., Clark R. C., Olsen C. W., Townsend H. G., Lunn D. P.: Immunization with recombinant modified vaccine Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 2006, 24, 1180-1190.
• 3.Breathnach C. C., Rudersdorf R., Lunn D. P.: Use of recombinant modified vaccina Ankara viral vectors for equine influenza vaccination. Vet. Immunol. Immunopath. 2003, 98, 127-136.
• 4.Chambers T. M., Holland R. E., Tudor L. R., Townsend H. G. G., Cook A., Bogdan J., Lunn D. P., Hussey S., Whitaker-Dowling P., Youngner J. S., Sebring R. W., Penner S. J., Stiegler G. L.: A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge. Equine Vet. J. 2001, 33, 630-636.
• 5.Chen Z., Sahashi Y., Matsuo K., Asanuma H., Takahashi H., Iwasaki T., Suzuki Y., Aizawa Ch., Kurata T., Tamura S.: Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 1998, 16, 1544-1549.
• 6.Cox R. J., Brokstad K. A., Ogra P.: Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live attenuated influenza vaccines. Scand. J. Immunol. 2004, 59, 1-15.
• 7.Daly J. M., Newton J. R., Mumford J. A.: Current perspectives on control of equine influenza. Vet. Res. 2004, 35, 411-423.
• 8.De Filette M., Min Jou W., Birkett A., Lyons K., Schultz B., Tonkyro A., Resch S., Fiers W.: Universal influenza A vaccine: Optimization of M2-based constructs. Virology 2005, 337, 149-161.
• 9.Dufour V.: DNA vaccines: new applications for veterinary medicine. Vet. Sci. Tommor. 2001, 2, 1-16.
• 10.Edlund Toulemonde C., Daly J., Sindle T., Guigal P. M., Audonnent J. C., Minke J. M.: Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 oubreak in the United Kindom. Vet. Rec. 2005, 156, 367-371.
• 11.Fouchier R. A. M., Osterhaus A. D. M. E., Brown I. H.: Animal influenza virus surveillance. Vaccine 2003, 21, 1754-1757.
• 12.Hannant D., Jessett D. M., O’Neil T., Sundquist B., Mumford J. A.: Nasopharyngeal, tracheobronchial and systemic immune responses to vaccination and aerosol infection with equine-2 influenza A virus (H3N8). Proc. Fifth Internat. Conf., Equine Infectious Diseases. University Press of Kentucky, Lexington 1987, 66-73.
• 13.Holmes M. A., Townsend H. G., Hussey S., Breathnach C., Barnett C., Holland R., Lunn D. P.: Immune responses to commercial equine vaccines. Int. Vet. Inf. Serv. 2003, P0630.1103.
• 14.Lunn D. P., Hussey S., Sebing R., Rushlow K. E., Radecki S. V., Whitaker-Dowling P., Youngner J. S., Chambers T. M., Holland R. E. Jr., Horohov D. W.: Safety, efficacy and immunogenicity of a modified-live equine influenza virus vaccine in ponies after induction of exercise-induced immunosuppression. J. Am. Med. Assoc. 2001, 218, 900-906.
• 15.Lunn D. P., Soboll G., Schram B. R., Quass J., McGregor M. W., Drape R. J., Macklin M. D., McCabe D. E., Swain W. F., Olsen C. W.: Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine 1999, 17, 2245-2258.
• 16.Minke J. M., Audonnet J.-Ch., Fischer L.: Equine viral vaccines: the past, present and future. Vet. Res. 2004, 35, 425-443.
• 17.Nayak D. P., Tobita K., Janda J. M., Davis A. R., De B. K.: Homologous interference mediated by defective interfering influenza virus derived from a temperature-sensitive mutant of influenza virus. J. Virol. 1978, 28, 375-386.
• 18.Neumann G., Fujii K., Kino Y., Kawaoka Y.: An improved reverse genetics system for influenza A virus generation and its implication for vaccine production. Proc. Natl. Acad. Sci. USA 2005, 102, 16825-16829.
• 19.Neumann G., Kawaoka Y.: Reverse genetics of influenza virus. Virology 2001, 287, 243-250.
• 20.Newton J. R., Lakhani K. H., Wood J. L. N., Baker D. J.: Risk factors for equine influenza serum antibody titres in young thoroughbred racehorses given an inactivated vaccine. Prev. Vet. Med. 2000, 46, 129-141.
• 21.Olsen Ch. W.: DNA vaccination against influenza viruses: a review with emphasis on equine and swine influenza. Vet. Microbiol. 2000, 74, 149-164.
• 22.Olsen Ch. W., McGregor M. W., Dybdahl-Sissoko N., Schram B. R., Nelson K. M., Lunn D. P., Macklin M. D., Swain W. F., Hinshaw V. S.: Immunogenecity and efficacy of baculovirus-expressed and DNA-based equine influenza virus hemagglutinin vaccines in mice. Vaccine 1997, 15, 1149-1156.
• 23.Paillot R., Hannant D., Kydd J. H., Daly J. M.: Vaccination against equine influenza: Quid novi? Vaccine 2006, 24, 4047-4061.
• 24.Palese P.: Making better influenza virus vaccines? Emerg. Infect. Dis. 2006, 12, 61-65.
• 25.Quinlivan M., Zamarin D., Garcia-Satre A., Cullinane A., Chambers T., Palese P.: Attenuation of equine influenza viruses through truncations of the NS1 protein. J. Virol. 2005, 79, 8431-8439.
• 26.Soboll G., Horohov D. W., Aldridge B. M., Olsen C. W., McGregor M. W., Drape R. J., Macklin M. D., Swain W. F., Lunn D. P.: Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. Vet. Immunol. Immunopathol. 2003, 94, 47-62.
• 27.Soboll G., Nelson K. M., Leuthner E. S., Clark R. J., Drape R., Macklin M. D., Swain W. F., Olsen C. W., Lunn D. P.: Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates o local IgA response. Vaccine 2003, 21, 3081-3092.
• 28.Timoney P. J.: Equine influenza. Comp. Immmun. Microbiol. Infect. Dis. 1996, 19, 205-211.